514 related articles for article (PubMed ID: 36768828)
1. Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs.
Casagrande GMS; Silva MO; Reis RM; Leal LF
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768828
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy and its role in an advanced clinical trial for lung cancer.
Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J
Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770
[TBL] [Abstract][Full Text] [Related]
3. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
4. Liquid biopsy in lung cancer management.
Irofei Zamfir MA; Buburuzan L; Hudiţă A; Gălăţeanu B; Ginghină O; Ion D; Motaş N; Ardeleanu CM; Costache M
Rom J Morphol Embryol; 2022; 63(1):31-38. PubMed ID: 36074665
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis, Monitoring, and Prognosis of Liquid Biopsy in Cancer Immunotherapy.
Kong W; Chen T; Li Y
Methods Mol Biol; 2023; 2695():127-143. PubMed ID: 37450116
[TBL] [Abstract][Full Text] [Related]
6. Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment.
Filipska M; Rosell R
Mol Oncol; 2021 Jun; 15(6):1667-1682. PubMed ID: 33969622
[TBL] [Abstract][Full Text] [Related]
7. Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer.
Qvick A; Stenmark B; Carlsson J; Isaksson J; Karlsson C; Helenius G
Mol Med; 2021 Jul; 27(1):68. PubMed ID: 34217228
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection.
Markou Α; Londra D; Tserpeli V; Kollias Ι; Tsaroucha E; Vamvakaris I; Potaris K; Pateras I; Kotsakis Α; Georgoulias V; Lianidou Ε
Clin Epigenetics; 2022 May; 14(1):61. PubMed ID: 35538556
[TBL] [Abstract][Full Text] [Related]
9. Liquid biopsy: current technology and clinical applications.
Nikanjam M; Kato S; Kurzrock R
J Hematol Oncol; 2022 Sep; 15(1):131. PubMed ID: 36096847
[TBL] [Abstract][Full Text] [Related]
10. Circulating epigenetic biomarkers in lung malignancies: From early diagnosis to therapy.
Tomasetti M; Amati M; Neuzil J; Santarelli L
Lung Cancer; 2017 May; 107():65-72. PubMed ID: 27312601
[TBL] [Abstract][Full Text] [Related]
11. EGFR mutation testing on plasma and urine samples: A pilot study evaluating the value of liquid biopsy in lung cancer diagnosis and management.
Satapathy S; Singh V; Nambirajan A; Malik PS; Tanwar P; Mehta A; Suryavanshi M; Thulkar S; Mohan A; Jain D
Curr Probl Cancer; 2021 Dec; 45(6):100722. PubMed ID: 33712318
[TBL] [Abstract][Full Text] [Related]
12. Liquid Biopsy in Lung Cancer: Biomarkers for the Management of Recurrence and Metastasis.
Souza VGP; Forder A; Brockley LJ; Pewarchuk ME; Telkar N; de Araújo RP; Trejo J; Benard K; Seneda AL; Minutentag IW; Erkan M; Stewart GL; Hasimoto EN; Garnis C; Lam WL; Martinez VD; Reis PP
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240238
[TBL] [Abstract][Full Text] [Related]
13. Advances in liquid biopsy-based markers in NSCLC.
Ren XD; Su N; Sun XG; Li WM; Li J; Li BW; Li RX; Lv J; Xu QY; Kong WL; Huang Q
Adv Clin Chem; 2023; 114():109-150. PubMed ID: 37268331
[TBL] [Abstract][Full Text] [Related]
14. Liquid biopsies based on DNA methylation as biomarkers for the detection and prognosis of lung cancer.
Li P; Liu S; Du L; Mohseni G; Zhang Y; Wang C
Clin Epigenetics; 2022 Sep; 14(1):118. PubMed ID: 36153611
[TBL] [Abstract][Full Text] [Related]
15. Liquid biopsy in breast cancer: A comprehensive review.
Alimirzaie S; Bagherzadeh M; Akbari MR
Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
[TBL] [Abstract][Full Text] [Related]
16. Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis.
Sands J; Li Q; Hornberger J
Lung Cancer; 2017 Aug; 110():19-25. PubMed ID: 28676213
[TBL] [Abstract][Full Text] [Related]
17. Liquid biopsy in CNS tumors: Current status & future perspectives.
Husain N; Husain A; Mishra S; Srivastava P
Indian J Pathol Microbiol; 2022 May; 65(Supplement):S111-S121. PubMed ID: 35562141
[TBL] [Abstract][Full Text] [Related]
18. Urine-Based Liquid Biopsy for Nonurological Cancers.
Jain S; Lin SY; Song W; Su YH
Genet Test Mol Biomarkers; 2019 Apr; 23(4):277-283. PubMed ID: 30986103
[TBL] [Abstract][Full Text] [Related]
19. Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC.
Behel V; Chougule A; Noronha V; Patil VM; Menon N; Singh A; Chopade S; Kumar R; Shah S; More S; Banavali SD; Chandrani P; Prabhash K
Clin Lung Cancer; 2022 Jul; 23(5):410-418. PubMed ID: 35649817
[TBL] [Abstract][Full Text] [Related]
20. Liquid biopsy tracking of lung tumor evolutions over time.
Russo A; De Miguel Perez D; Gunasekaran M; Scilla K; Lapidus R; Cooper B; Mehra R; Adamo V; Malapelle U; Rolfo C
Expert Rev Mol Diagn; 2019 Dec; 19(12):1099-1108. PubMed ID: 31608732
[No Abstract] [Full Text] [Related]
[Next] [New Search]
